Condition

HER2-Negative Breast Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials7

Recruiting2

Common interventions11

Lead sponsors shown7

Clinical trials

7 shown

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With AnlotinibNCT07396454 · 2026-02-10

RECRUITING

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast CancerNCT06518837 · 2024-10-30

RECRUITING

SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast CancersNCT07844759 · 2027-01-01

NOT_YET_RECRUITING

A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During TreatmentNCT07827573 · 2026-10-30

NOT_YET_RECRUITING

Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B MutationNCT03989089 · 2020-07-03

ACTIVE_NOT_RECRUITING

Ribociclib + PDR001 in Breast Cancer and Ovarian CancerNCT03294694 · 2017-11-08

TERMINATED

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and TaxanesNCT02225470 · 2013-09-26

COMPLETED

Common interventions

E7389 (Eribulin Mesylate)DRUG1 Endocrine TherapyDRUG1 FulvestrantDRUG1 GiredestrantDRUG1 PDR001DRUG1 PembrolizumabDRUG1 Radiotherapy Combined with Anlotinib and a Microtubule InhibitorDRUG1 RibociclibDRUG1 Stereotactic Radiation TherapyRADIATION1 TirzepatideDRUG1 Vinorelbine injectionDRUG1

Leading sponsors

Dana-Farber Cancer Institute1 Eisai Co., Ltd.1 Hoffmann-La Roche1 Renaissance Institute of Precision Oncology and Radiosurgery1 Rutgers, The State University of New Jersey1 The First Affiliated Hospital with Nanjing Medical University1 University of Malaya1

Trial status mix

NOT_YET_RECRUITING2

RECRUITING2

ACTIVE_NOT_RECRUITING1

COMPLETED1

TERMINATED1

Phase mix

PHASE23

PHASE32

NA1

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.